等待开盘 11-05 09:30:00 美东时间
0.000
NaN.00%
Results from the Phase 1 CARLYSLE study of obe-cel in severe refractory systemic lupus erythematosus (srSLE) indicate promising safety and efficacy, with no ICANS or high-grade CRS observed. The 50 million cell dose has been selected for the Phase 2 pivotal study, showcasing responses in 83% of patients achieving remission and 50% achieving complete renal response. All patients reduced steroid use to 5mg by month six, supporting the progression o...
10-27 11:00
RREEF Property Trust, Inc. Class A ( ($ZRPTAX) ) has shared an announcement. RR...
08-30 02:18
An announcement from RREEF Property Trust, Inc. Class A ( ($ZRPTAX) ) is now av...
06-02 21:28
LODAS executed 1.35 million shares in second quarter OVERLAND PARK, Kan., Aug. 8, 2023 /PRNewswire/ -- LODAS Markets, the third-largest alternatives market operator in the U.S., today announ...
2023-08-08 23:06